Chidozie Ugwumba Sells 26,105 Shares of Clene (NASDAQ:CLNN) Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 26,105 shares of Clene stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $4.89, for a total value of $127,653.45. Following the completion of the transaction, the insider owned 682,482 shares of the company’s stock, valued at $3,337,336.98. This trade represents a 3.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Thursday, January 15th, Chidozie Ugwumba sold 12,563 shares of Clene stock. The stock was sold at an average price of $5.10, for a total value of $64,071.30.
• On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The shares were sold at an average price of $5.12, for a total transaction of $100,459.52.
• On Monday, January 12th, Chidozie Ugwumba sold 32,705 shares of Clene stock. The stock was sold at an average price of $5.50, for a total transaction of $179,877.50.
• On Friday, January 9th, Chidozie Ugwumba sold 9,075 shares of Clene stock. The shares were sold at an average price of $6.27, for a total transaction of $56,900.25.
• On Thursday, January 8th, Chidozie Ugwumba sold 3,195 shares of Clene stock. The stock was sold at an average price of $6.09, for a total transaction of $19,457.55.
• On Wednesday, January 7th, Chidozie Ugwumba sold 3,938 shares of Clene stock. The stock was sold at an average price of $6.29, for a total transaction of $24,770.02.
• On Tuesday, January 6th, Chidozie Ugwumba sold 3,111 shares of Clene stock. The stock was sold at an average price of $6.04, for a total value of $18,790.44.
• On Monday, January 5th, Chidozie Ugwumba sold 5,869 shares of Clene stock. The stock was sold at an average price of $5.87, for a total value of $34,451.03.
• On Friday, January 2nd, Chidozie Ugwumba sold 4,015 shares of Clene stock. The shares were sold at an average price of $5.73, for a total transaction of $23,005.95.
• On Wednesday, December 31st, Chidozie Ugwumba sold 13,095 shares of Clene stock. The stock was sold at an average price of $5.81, for a total transaction of $76,081.95.

Clene Stock Down 1.2%

CLNN stock opened at $5.05 on Friday. The stock has a market cap of $54.79 million, a PE ratio of -1.49 and a beta of 0.87. The firm’s 50-day simple moving average is $7.14 and its 200 day simple moving average is $6.47. Clene Inc. has a fifty-two week low of $2.28 and a fifty-two week high of $13.50.

Clene (NASDAQ:CLNN) last posted its earnings results on Thursday, November 13th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.06 million. Equities analysts forecast that Clene Inc. will post -5.19 EPS for the current fiscal year.

Clene News Roundup

Here are the key news stories impacting Clene this week:

• Positive Sentiment: JonesTrading reiterated a “Buy” rating on CLNN, signaling continued analyst conviction and a bullish view that could support the stock if clinical or corporate catalysts materialize. JonesTrading Sticks to Their Buy Rating for Clene (CLNN)
• Positive Sentiment: An independent director recently purchased $216,664.50 of CLNN shares, a meaningful insider buy that can be interpreted as management/board confidence and sometimes helps stabilize a share price. Insider Buying: Clene Director Purchases Stock
• Neutral Sentiment: Management is presenting at the Emerging Growth Conference (investor visibility event). Such presentations can generate new investor interest but typically require follow‑up data or guidance to move the stock materially. Clene to Present at the Emerging Growth Conference
• Negative Sentiment: Major shareholder Chidozie Ugwumba has been selling large blocks of CLNN repeatedly in January (multiple filings show roughly 100k+ shares sold across early–mid January), reducing his stake and supplying shares to the market — a strong downward pressure signal for traders. Major Shareholder Sells in Multiple Transactions

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on CLNN shares. D. Boral Capital reiterated a “buy” rating and set a $23.00 price objective on shares of Clene in a research note on Friday, January 9th. Benchmark reissued a “buy” rating on shares of Clene in a research note on Thursday, December 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Clene in a report on Friday, January 9th. Finally, UBS Group reaffirmed a “buy” rating on shares of Clene in a report on Wednesday, December 3rd. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $32.60.

Institutional Trading of Clene

Several large investors have recently added to or reduced their stakes in CLNN. Jones Financial Companies Lllp acquired a new stake in Clene during the 3rd quarter worth about $29,000. Jane Street Group LLC bought a new stake in shares of Clene in the 2nd quarter valued at approximately $47,000. Lunt Capital Management Inc. increased its holdings in Clene by 71.2% in the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock worth $199,000 after buying an additional 21,217 shares during the last quarter. Finally, Scoggin Management LP raised its position in Clene by 42.8% during the second quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after acquiring an additional 42,750 shares in the last quarter. 23.28% of the stock is owned by institutional investors and hedge funds.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).